GSK initiates a Phase III efficacy trial for FLUm3HA.b-3NA by September 30, 2026.

Question

Six frontier AI models put this at 65% by 16 Oct 2026. Full reasoning from every model.

WillHappen.ai · Accepted Answer

65% — the median of 6 frontier models, resolving by 2026-10-16.

Answer

Gemini (Google): 88% — GSK has primed Phase III initiation for September 2026, leaving minimal operational friction to hit before October 16. Clinical trial site activation or first patient dosing typically follows swiftly once a planned start month is formally guided. A minor protocol or regulatory delay past September 30 is cushioned by the October 16 resolution buffer. Only a sudden safety hold from Phase II follow-up or a contract manufacturing snag would halt this late-stage pipeline priority.

Answer

Claude (Anthropic): 58% — Whether GSK's Phase III start slips past Sept 30 given typical trial-launch delays despite stated plans. GSK has publicly signaled a September 2026 Phase III start, indicating late-stage readiness and regulatory alignment already underway. Phase III launches for major pharma candidates frequently slip 1-3 months due to site activation, IRB approvals, and enrollment logistics. A confirmed trial registry listing (ClinicalTrials.gov) with a first-patient-dosed date before Sept 30 would resolve this decisively yes.

Answer

GPT (OpenAI): 72% — This mainly depends on whether GSK files the trial start on schedule rather than slipping it weeks for operational reasons. GSK controls the decision, and reported September plans put the expected start inside the remaining two-week window. Phase III vaccine studies commonly slip from announced months because site activation, supply release, or protocol clearance can lag. A registry posting, first-site activation, or GSK confirmation before September 30 would sharply raise confidence.

Answer

Grok (xAI): 58% — GSK listing a first-patient-in date of 30 Sep 2026 or earlier on ClinicalTrials.gov. GSK must finish ethics/regulatory sign-off and site activation; that typically takes 4–8 weeks after a go decision. Early-September announcement of a September start already leaves only two weeks and no NCT number has appeared. Seasonal flu Phase 3s frequently slip a year; missing NH 2026–27 reduces pressure to start this month.

Answer

DeepSeek (DeepSeek): 22% — Whether GSK's own September 2026 Phase III start actually happens, or slips past the 14-day window. GSK's mRNA flu program has repeatedly slipped timelines; a Phase III start announced for September 2026 would need to launch within two weeks of today. A Phase III efficacy trial requires FDA/regulatory clearance, site activation, and enrollment infrastructure that typically takes months after a Phase II readout. Base rate for announced vaccine Phase III starts hitting their stated month is roughly 30-40%, and this candidate has no prior Phase III track record.

Answer

Qwen (Alibaba): 72% — GSK has publicly signaled September 2026 Phase III start; execution risk is the main drag. GSK's own stated timeline targets September 2026 initiation, and large pharma rarely misses self-announced Phase III starts by more than a few weeks. Phase III initiation requires site activation and IRB/ethics approvals; these are typically locked in before public announcements, reducing slip risk. A 2–4 week regulatory or manufacturing delay could push past Sept 30; would move to ~85 if ClinicalTrials.gov listing appeared today.

GSK initiates a Phase III efficacy trial for FLUm3HA.b-3NA by September 30, 2026.

The US FDA approves an anti-aging therapeutic indicated specifically to slow biological aging before 2035.

A fully lab-grown solid organ is successfully transplanted into a human patient in a clinical trial before 2032.

The US FDA approves a gene therapy targeting sensorineural hearing loss before 2030.

A gene editing therapy for herpes simplex virus enters Phase 3 clinical trials before 2029.